Pharma Times: Artificial intelligence (AI) health technology company, Anumana, will collaborate with Pfizer to develop an artificial intelligence electrocardiogram algorithm (AI-ECG), which enables the early detection of cardiac amyloidosis.

Anumana acquires NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP)

Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has announced a new multi-year deal with Pfizer focused on improving the identification and diagnosis of cardiac…

The rapid growth and widespread adoption of large language models (LLMs) across real-world applications offer a host of new opportunities for the healthcare sector. Hospitals and clinics are starting to…